Patent application number | Description | Published |
20080262039 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions - Vanilloid receptor ligand compounds corresponding to formula I: | 10-23-2008 |
20080269289 | Vanilloid receptor ligand compounds, pharmaceutical compositions containing them, a method of producing them and the use thereof to treat pain and various other conditions - Compounds corresponding to formula I: | 10-30-2008 |
20080275044 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions - Compounds corresponding to formula I: | 11-06-2008 |
20080306161 | Use of Axomadol for Treatment of Arthrosis Pain - The use of axomadol for the treatment of pain in arthrosis. | 12-11-2008 |
20090076086 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF - Substituted nicotinamide compounds corresponding to formula I | 03-19-2009 |
20090156590 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions - Vanilloid receptor ligand compounds corresponding to formula I: | 06-18-2009 |
20090264400 | Substituted Sulfonamide Compounds - Substituted sulfonamide compounds corresponding to formula I: | 10-22-2009 |
20090298812 | Substituted Sulfonamide Compounds - Substituted sulfonamide compounds corresponding to the formula I | 12-03-2009 |
20100063009 | Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1.3-diol and an NSAID - A combination comprising (a) at least one 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol component, and (b) at least one non-steroidal anti-inflammatory drug (NSAID) component; a pharmaceutical composition and a dosage form comprising such as combination, and a method of treating pain and/or ostheoarthritis in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to said mammal, in which component (a) may be administered before or after component (b), and in which components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 03-11-2010 |
20100063148 | Pharmaceutical Combination - A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 03-11-2010 |
20100069501 | Pharmaceutical Composition Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and Paracetamol - A combination comprising (a) at least one 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol component, and (b) Paracetamol or a derivative thereof; a pharmaceutical composition and/or dosage form comprising such a combination as well as a method of treating one or more of pain and ostheoarthritis in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to said mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 03-18-2010 |
20100105722 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators - Substituted tetrahydrothienopyridines corresponding to formula (1) | 04-29-2010 |
20100190752 | Pharmaceutical Combination - A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 07-29-2010 |
20100280128 | Use of 1-phenyl-3-dimethylaminopropane Compounds for Treating Rheumatoid Pain - The use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of rheumatoid pain, especially rheumatoid arthritic pain, very especially preferably chronic rheumatoid arthritic pain. | 11-04-2010 |
20100331381 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands - The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions. | 12-30-2010 |
20100331424 | Use of Axomadol for Treatment of Arthrosis Pain - The use of axomadol for the treatment of pain in arthrosis. | 12-30-2010 |
20110003795 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands - The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions. | 01-06-2011 |
20110053914 | Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic - A pharmaceutical combination comprising: | 03-03-2011 |
20110184020 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions - Vanilloid receptor ligand compounds corresponding to formula I: | 07-28-2011 |
20110301156 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions - Vanilloid receptor ligand compounds corresponding to formula I: | 12-08-2011 |
20110306674 | Pharmaceutical Combination - A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration. | 12-15-2011 |
20120004317 | Tapentadol for use in the treatment of irritable bowel syndrome - The invention relates to tapentadol for use in the treatment of Irritable Bowel Syndrome | 01-05-2012 |
20120022294 | Axomadol or a Metabolite Thereof for Use in the Treatment of Irritable Bowel Syndrome - The invention relates to axomadol or a metabolite thereof for use in the treatment of irritable bowel syndrome. | 01-26-2012 |
20120046301 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor - Substituted cyclic carboxamide and urea compounds, a process for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for the treatment and/or inhibition of pain and other conditions mediated by the vanilloid receptor 1. | 02-23-2012 |
20120258946 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands - Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions. | 10-11-2012 |
20120302602 | Vanilloid Receptor Ligand Compounds, Pharmaceutical Compositions Containing Them, a Method of Producing Them and the Use Thereof to Treat Pain and Various Other Conditions - Compounds corresponding to formula I: | 11-29-2012 |
20120309840 | Treatment of Pain Associated with Trigeminal Neuralgia - The use of tapentadol for the treatment of pain associated with disorders of the trigeminal nerve, in particular for use in the treatment of pain associated with trigeminal neuralgia. | 12-06-2012 |
20120309841 | Method of Inhibiting Chronification of Pain - The use of tapentadol in the treatment of pain and/or pain chronification in a subject suffering from pain chronification and/or in the treatment of pain and inhibition of pain chronification in a subject suffering from pain and at risk of pain chronification, as well as the use of tapentadol for the treatment or inhibition of migraine. | 12-06-2012 |
20130116334 | Treatment of Irritable Bowel Syndrome - A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol. | 05-09-2013 |
20130310371 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexa- ne-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof. | 11-21-2013 |
20130310435 | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from paracetamol and propacetamol. | 11-21-2013 |
20130317075 | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexa- ne-1,1'-pyrano[3,4,b]indol]-4-amine and a NSAR - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a non-steroidal anti-rheumatic drug selected from the group consisting of indometacin, diclofenac, sulindac, tolmetin, zomepirac, aclofenac, bumadizone, etodolac, lonazolac, fentiazac, acemetacin, difenpiramide, oxametacin, proglumetacin, ketorolac, aceclofenac, bufexamac, mefenamic acid, tolfenamic acid, flufenamic acid, meclofenamic acid, and the physiologically acceptable salts thereof. | 11-28-2013 |
20130317076 | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexa- ne-1,1'-pyrano-[3,4,b]indol]-4-amine and a Salicylic Acid Component - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a salicylic acid component selected from the group consisting of acetylsalicylic acid, salicylic acid, salicylamide, ethenzamide, salsalate, dipyrocetyl, benorilate, diflunisal, guacetisal, and the physiologically acceptable salts thereof. | 11-28-2013 |
20130324581 | Pharmaceutical Composition Comprising (1r,4r)-6'-flouro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexa- ne-1,1'-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is a propionic acid derivative selected from the group consisting of ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, fenbufen, suprofen, pirprofen, indoprofen, tiaprofenic acid, oxaprozin, ibuproxam, flunoxaprofen, alminoprofen, naproxcinod, and the physiologically acceptable salts thereof. | 12-05-2013 |
20140142143 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands - The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions. | 05-22-2014 |
20140309311 | Pharmaceutical Combination - A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration. | 10-16-2014 |